Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

US Payers Rate ICER Assessment Updates Using Real World Data As Potentially ‘High Impact’

Dec 01 2020

• By Cathy Kelly

ICER Will Pilot Use Of RWE In Drug Assessment Updates

Related Content

High-Priced Drugs For Rare Disease: Leading US Payers Discuss Cost Concerns, Value-Based Contracts And ICER

Jun 15 2020

ICER Will Assess Real World Evidence On Accelerated Approvals After Two Years

Feb 06 2020

Biden, Germany And Bringing A National Drug Pricing Negotiation Process To US

Oct 23 2020

Additional Topics

United States Real-World Evidence Cost Effectiveness Reimbursement Policy Health Technology Assessment BioPharmaceutical

More from Real-World Evidence

More from Clinical Trials

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window